Registry
Module Specifications
Archived Version 2018 - 2019
| |||||||||||||||||||||||||||||||||||||||||
Description The module is intended to introduce the regulatory context in which medicinal products, particularly those produced through biotechnology processes, are developed and made available to patients. The module sets out to explain and develop the working interface between science, technology, manufacturing processes and the licensing/regulatory environment which controls medicines. The global organisation of relevant regulation is outlined, particularly the roles of ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use), CFR (Code of Federal Regulations) and EU. Due emphasis is placed on issues related to establishment of quality standards for biotechnology derived products as well as the required information on safety and efficacy as appropriate. There are obvious interrelationships and connections to other modules e.g. GMP, material characterization, formulation and analytical technologies and methodologies. These are not repetitive treatments of the same subject but a necessary distinction to accommodate difference in depth in specific areas e.g. characterization and stability in a second treatment. The significance of ICH Q8, 9 and 10 is also discussed. The module will also address regulatory issues surrounding Clinical Trials, Pharmacovigilance and Biosimilars. | |||||||||||||||||||||||||||||||||||||||||
Learning Outcomes 1. Demonstrate an understanding of the global regulatory framework for biotechnology derived pharmaceuticals 2. Demonstrate an understanding of how the nature and production of biotechnology products affects quality, safety and efficacy 3. Discuss key EU Directives and Institutions (MEA, CHMP, CVMP) 4. Describe the relevance to regulatory affairs of clinical trials 5. Demonstrate an understanding of the elements of the CTD (Common Technical Document) 6. Discuss the regulatory approaches to Biosimilars 7. Demonstrate an understanding of the role of Pharmacovigilance and ICH Q10 | |||||||||||||||||||||||||||||||||||||||||
All module information is indicative and subject to change. For further information,students are advised to refer to the University's Marks and Standards and Programme Specific Regulations at: http://www.dcu.ie/registry/examinations/index.shtml |
|||||||||||||||||||||||||||||||||||||||||
Indicative Content and
Learning Activities Regulatory Affairs Science for Biotechnology Products PreambleIntroduction to the regulatory context in which medicinal products and specifically those from biotechnology processes are developed and made available to patients throughout the product lifecycle. Sources of information for Regulatory Affairs.General Attributes and legal status of Biological/Biotechnological Medicinal ProductsSummary issues related to the development, characterization and specifications of biotechnology derived products; Stability issues relevant to biotechnology products; Biosimilars.Regulatory Framework - GeneralNational aspects; Health Products Regulatory Authority (HPRA), European aspects (European Medicines Agency EMA), International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).Regulatory Framework - Particular VariationProcess change and ComparabilityThe Common Technical Document (CTD)Regulatory Aspects of ICH Q8,9 and 10(Pharmaceutical Development, Quality Risk Management and Pharmaceutical Quality System)PharmacovigilanceClinical Trials | |||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
Indicative Reading List
| |||||||||||||||||||||||||||||||||||||||||
Other Resources 11463, Website, European Medicines Agency, 0, CHMP (Committee for Medicinal Products for Human Use); CVMP (Committee for Medicinal Products for Veterinary Use); COMP (Committee for Orphan Medicinal Products); HMPC (Committee on Herbal Medicinal Products)., http://www.ema.europa.eu/ema/, 11455, Website, 0, ICH Information, http://www.ich.org, 11456, Website, 0, FDA CFR, http://www.gpoaccess.gov/cfr/index.html, 11457, Website, 0, CTD Information, http://www.ich.org/products/ctd.html, 11458, Website, 0, International Federation of Pharmaceutical Manufacturers & Associations, http://www.ifpma.org/, 11459, Website, 0, Health Products Regulatory Authority, http://www.hpra.ie, 11460, Website, 0, The European Pharmacopoeia (Pharmacopoea Europaea, Ph.Eur.), 11461, Website, 0, The United States Pharmacopeia (USP), | |||||||||||||||||||||||||||||||||||||||||
Programme or List of Programmes |
GCBE | Graduate Cert in Bioprocess Engineering |
GDBE | Graduate Dip in Bioprocess Engineering |
MSBE | MSc in Bioprocess Engineering |
SAMPB | STAND ALONE MODULE (BIOTECHNOLOGY) |
- See the module specification for BE585 in 2003 - 2004
- See the module specification for BE585 in 2004 - 2005
- See the module specification for BE585 in 2005 - 2006
- See the module specification for BE585 in 2006 - 2007
- See the module specification for BE585 in 2007 - 2008
- See the module specification for BE585 in 2008 - 2009
- See the module specification for BE585 in 2009 - 2010
- See the module specification for BE585 in 2010 - 2011
- See the module specification for BE585 in 2011 - 2012
- See the module specification for BE585 in 2012 - 2013
- See the module specification for BE585 in 2013 - 2014
- See the module specification for BE585 in 2014 - 2015
- See the module specification for BE585 in 2015 - 2016
- See the module specification for BE585 in 2016 - 2017
- See the module specification for BE585 in 2017 - 2018
- See the module specification for BE585 in 2018 - 2019
- See the module specification for BE585 in 2019 - 2020
- See the module specification for BE585 in 2020 - 2021
- See the module specification for BE585 in 2021 - 2022
- See the module specification for BE585 in 2022 - 2023
- See the module specification for BE585 in 2023 - 2024
- See the module specification for the current year